Regeneron Pharmaceuticals Inc (MIL:1REGN)
€ 757 -25.2 (-3.22%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 79/100

Regeneron Pharmaceuticals Inc at Credit Suisse Biotech Conference Transcript

Jun 22, 2020 / 12:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the virtual fireside chat with Regeneron Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions). I would like to hand the conference over to your speaker today, Evan Seigerman. Please go ahead.

Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

Thank you, operator. Thanks for joining us this morning. It's my pleasure to have with us on the phone Regeneron. And from Regeneron, we have Bob Landry, CFO; Israel Lowy, SVP Translational Science and Oncology; Neil Stahl, EVP of R&D, currently focused on the COVID-19 program, Justin Holko from the IR team. And just before we get started, I want to read a quick disclosure statement for everyone on the call. By accepting this invitation and dialing into this event you consent to having your contact information being provided to the corporate presenters so they may better understand their audience and ensure

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot